Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug

MT Newswires Live

2024/11/22

Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.

A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.

ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485762284"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485762284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485762284?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 15:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485762284","market":"sg","top_or_hot":-1,"title":"Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug","media":"MT Newswires Live","content":"<html><body><p> Abbisko Cayman (HKG:2256) unit Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.</p><p>A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.</p><p>ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-22 15:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Abbisko Cayman (HKG:2256) unit Abbisko <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.</p><p>A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.</p><p>ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485762284","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485762284","pubTimestamp":1732260321,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Abbisko Cayman  unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02256":"和誉-B","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"Abbisko实体瘤药物II期研究首例胃癌患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":0.9},"content_text":"Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}